Covax, a global program to supply vaccines to poorer countries, plans to ship over 300 million doses by June 30.
Some U.S. doctors, burned by low reimbursements, have stopped testing for the virus.
Iran announced that its first batch of Covid-19 vaccine, Russia’s Sputnik V, would arrive on Thursday.
Get the latest updates here, as well as maps and vaccines in development.
Good news about vaccines
For once, we have some good news to talk about: the prospect of another vaccine coming online in the U.S., and a long-awaited indication that at least one vaccine reduces transmission, not just the severity of Covid-19.
Let’s start with the remarkable turnaround of the experimental vaccine from Novavax, a Maryland-based company that has never before brought a vaccine to market.
Last fall, Novavax postponed U.S. clinical trials because of manufacturing delays, jeopardizing the company’s $1.6 billion federal contract and leaving some to wonder whether they should write off the company’s shot entirely. In December, Novavax watched from the sidelines as the Pfizer-BioNTech and Moderna vaccines were approved.
But things have changed. Novavax announced last week that its vaccine produced robust protection in a large British trial and that it worked — although far less well — in a smaller study in South Africa. The company has also been able to quickly recruit volunteers for its U.S. trials because the two authorized vaccines have been difficult to get, and many see the Novavax trial as their best chance to get vaccinated.
So the company now stands a chance of having trial results this spring, with possible government authorization as early as April. If everything goes well, and that is a big if, Novavax could deliver enough additional doses to vaccinate 55 million Americans by the end of June. That would be on top of the 400 million doses that Moderna and Pfizer are contracted to supply the U.S. by the middle of the year — enough for 200 million people.
It gets better: Novavax has been laying the international groundwork for the eventual production of two billion doses per year — and its vaccine, unlike Moderna and Pfizer’s, can be stored and shipped at normal refrigeration temperatures.
As for protection against transmission, AstraZeneca recently released a report that offered an answer to one of the pandemic’s big questions: Will vaccines prevent people from giving the virus to others?
Researchers from the University of Oxford and AstraZeneca have found that not only did their vaccine protect people from serious illness and death but also had the potential to reduce transmission. Swabs taken from trial participants showed a 67 percent reduction in virus being detected among those vaccinated, though scientists warned that the data was preliminary and that masking remained necessary for all.
The AstraZeneca-Oxford vaccine is in U.S. trials, and the company has a deal to supply 300 million doses, enough for another 150 million people.
The New York Times
Me: “The AstraZeneca-Oxford vaccine is in U.S. trials”, let’s hope it does better than not much good for anything reviews which it currently seems to have.